The investigators propose to conduct a randomized double-blind, parallel-group, placebo-controlled trial of mifepristone in veterans with military-related posttraumatic stress disorder (PTSD). This study will examine the clinical, neuropsychological, and neuroendocrine effects of short-term treatment of mifepristone (600 mg/day for one week) to determine if this treatment is efficacious in improving PTSD symptoms, cognitive functioning, or other related clinical measures. Additionally, the investigators will observe whether baseline neuroendocrine activity, or other clinical or neuropsychological factors predict the response to mifepristone, and whether mifepristone-induced changes in neuroendocrine activity are associated with treatment outcome.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Masking
TRIPLE
Enrollment
80
600 mg/day x 1 week
placebo
James J. Peters VA Medical Center
The Bronx, New York, United States
RECRUITINGChange from baseline on the total severity of the CAPS-2 and dichotomously defined clinical responder status.
Time frame: baseline, endpoint, 4 week follow-up
Change in cognitive functioning as measured by the MATRICS neuropsychological test battery and self-reported measures of depression and PTSD.
Time frame: baseline, endpoint, 4 week follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.